Cellply, VivaCyte

Cellply Italy California

07.08.2025 - 18:07:21

Cellply launches its end-to-end single cell potency characterization platform VivaCyte

Integrates potency analysis and immunophenotyping to streamline cell therapy R&Dthe successful conclusion of an internal funding round of €3.6 million and extended the round to new investors.   

To find out more visit: cellply.com

Media contact: press@cellply.com

Cellply leaders Emiliano Spagnolo and Massimo Bocchi with the new VivaCyte single cell potency characterization platform

Logo - https://mma.prnewswire.com/media/2319836/Cellply_mainlogo_positive_Logo.jpg
Photo - https://mma.prnewswire.com/media/2319838/GUI_0488.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/cellply-launches-its-end-to-end-single-cell-potency-characterization-platform-vivacyte-302036598.html

@ prnewswire.co.uk